Physician profile
Amanda Dancy Bundy
NPI 1063049963
$1,723.47
in general payments reported to CMS, 2019-2025
20 companies · $677 in 2025
The $677 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.23 · 2022: $333 · 2023: $376 · 2024: $319 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,372.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $378.39 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $208.39 | 2022-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $160.09 | 2022-2025 | |
| Novo Nordisk INC | $143.54 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.54 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $85.64 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $84.38 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $81.18 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $81.10 | 2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $77.98 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $61.18 | 2024-2025 | Mounjaro |
| Mylan Specialty L.P. | $57.20 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.35 | 2023-2025 | Caplyta |
| Dexcom, INC. | $25.27 | 2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $20.73 | 2025 | Symbravo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $20.10 | 2025 | Yupelri |
| Pfizer INC. | $18.78 | 2023 | |
| Tris Pharma INC | $17.66 | 2025 | Dyanavel Xr |
| Astellas Pharma US INC | $16.29 | 2024 | Veozah |
| Irhythm Technologies, INC. | $12.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Bundy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.